JP2018535929A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535929A5 JP2018535929A5 JP2018515603A JP2018515603A JP2018535929A5 JP 2018535929 A5 JP2018535929 A5 JP 2018535929A5 JP 2018515603 A JP2018515603 A JP 2018515603A JP 2018515603 A JP2018515603 A JP 2018515603A JP 2018535929 A5 JP2018535929 A5 JP 2018535929A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- concentration
- pharmaceutical formulation
- item
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 46
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 36
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 36
- 241000700605 Viruses Species 0.000 claims description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 108010054218 Factor VIII Proteins 0.000 claims description 18
- 102000001690 Factor VIII Human genes 0.000 claims description 18
- 239000003246 corticosteroid Substances 0.000 claims description 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- 210000000234 capsid Anatomy 0.000 claims description 12
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 12
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 229920001993 poloxamer 188 Polymers 0.000 claims description 12
- 229940044519 poloxamer 188 Drugs 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 12
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 10
- 208000009292 Hemophilia A Diseases 0.000 claims description 10
- 208000032843 Hemorrhage Diseases 0.000 claims description 7
- 208000034158 bleeding Diseases 0.000 claims description 7
- 230000000740 bleeding effect Effects 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 4
- 239000004067 bulking agent Substances 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004904 shortening Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229960000301 factor viii Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 61
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021181755A JP2022010141A (ja) | 2015-09-24 | 2021-11-08 | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
| JP2024120967A JP2024147801A (ja) | 2015-09-24 | 2024-07-26 | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232242P | 2015-09-24 | 2015-09-24 | |
| US62/232,242 | 2015-09-24 | ||
| US201662323182P | 2016-04-15 | 2016-04-15 | |
| US62/323,182 | 2016-04-15 | ||
| US201662365544P | 2016-07-22 | 2016-07-22 | |
| US62/365,544 | 2016-07-22 | ||
| PCT/US2016/053269 WO2017053677A1 (en) | 2015-09-24 | 2016-09-23 | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021181755A Division JP2022010141A (ja) | 2015-09-24 | 2021-11-08 | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018535929A JP2018535929A (ja) | 2018-12-06 |
| JP2018535929A5 true JP2018535929A5 (enExample) | 2019-10-31 |
Family
ID=57113749
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515603A Withdrawn JP2018535929A (ja) | 2015-09-24 | 2016-09-23 | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
| JP2021181755A Pending JP2022010141A (ja) | 2015-09-24 | 2021-11-08 | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
| JP2024120967A Pending JP2024147801A (ja) | 2015-09-24 | 2024-07-26 | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021181755A Pending JP2022010141A (ja) | 2015-09-24 | 2021-11-08 | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
| JP2024120967A Pending JP2024147801A (ja) | 2015-09-24 | 2024-07-26 | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10512675B2 (enExample) |
| EP (1) | EP3352787A1 (enExample) |
| JP (3) | JP2018535929A (enExample) |
| KR (1) | KR102805910B1 (enExample) |
| CN (1) | CN108778323A (enExample) |
| AU (2) | AU2016326602A1 (enExample) |
| BR (1) | BR112018006074A2 (enExample) |
| CA (1) | CA2999297A1 (enExample) |
| CL (1) | CL2018000740A1 (enExample) |
| IL (2) | IL297353B1 (enExample) |
| MA (1) | MA42934A (enExample) |
| MX (1) | MX2018003702A (enExample) |
| PE (2) | PE20181338A1 (enExample) |
| PH (1) | PH12018500594A1 (enExample) |
| RU (2) | RU2742352C2 (enExample) |
| TW (3) | TWI756185B (enExample) |
| WO (1) | WO2017053677A1 (enExample) |
| ZA (1) | ZA201801657B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| MA42934A (fr) * | 2015-09-24 | 2018-08-01 | Biomarin Pharm Inc | Vecteurs de facteur viii à virus adéno-associé, particules virales associées et formulations thérapeutiques comprenant ceux-ci |
| MY189674A (en) | 2015-10-28 | 2022-02-24 | Sangamo Therapeutics Inc | Liver-specific constructs, factor viii expression cassettes and methods of use thereof |
| IL263801B2 (en) | 2016-07-26 | 2024-01-01 | Biomarin Pharm Inc | Novel adeno-associated virus capsid proteins |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7764129B2 (ja) * | 2017-07-10 | 2025-11-05 | ユニキュアー アイピー ビー．ブイ． | ヒトにおけるａａｖ遺伝子療法のための手段及び方法 |
| WO2019028192A1 (en) * | 2017-08-01 | 2019-02-07 | Spark Therapeutics, Inc. | METHODS OF GENE THERAPY TARGETING FACTOR VIII (FVIII) |
| MA51753A (fr) * | 2018-02-05 | 2020-12-16 | Audentes Therapeutics Inc | Éléments de régulation de la transcription et utilisations associées |
| US20210093735A1 (en) * | 2018-04-26 | 2021-04-01 | The University Of North Carolina At Chapel Hill | Methods and compositions for treatment of hemophilia |
| WO2019217513A2 (en) | 2018-05-09 | 2019-11-14 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| EP3794112A1 (en) * | 2018-05-14 | 2021-03-24 | BioMarin Pharmaceutical Inc. | Stable expression of aav vectors in juvenile subjects |
| MX2020012077A (es) | 2018-05-15 | 2021-03-09 | Voyager Therapeutics Inc | Composiciones y metodos para el tratamiento de la enfermedad de parkinson. |
| KR20210034013A (ko) * | 2018-07-16 | 2021-03-29 | 박스알타 인코퍼레이티드 | 발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법 |
| BR112021001315A2 (pt) * | 2018-08-03 | 2021-04-27 | Sangamo Therapeutics, Inc. | parâmetros clínicos melhorados através da expressão do fator viii |
| JP2021533805A (ja) * | 2018-08-24 | 2021-12-09 | スパーク セラピューティクス インコーポレイテッドSpark Therapeutics, Inc. | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
| SG11202103151RA (en) | 2018-09-28 | 2021-04-29 | Voyager Therapeutics Inc | Frataxin expression constructs having engineered promoters and methods of use thereof |
| AU2020221340A1 (en) | 2019-02-15 | 2021-09-16 | Bayer Healthcare Llc | Gene editing for hemophilia A with improved Factor VIII expression |
| CA3133255A1 (en) | 2019-03-13 | 2020-09-17 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
| WO2020247814A1 (en) * | 2019-06-05 | 2020-12-10 | Orchard Therapeutics (Europe) Limited | Compositions and methods for modifying eukaryotic cells |
| US20200405883A1 (en) * | 2019-06-20 | 2020-12-31 | Baxalta Incorporated | Method of treatment with viral-based gene therapy |
| WO2021084276A2 (en) | 2019-11-01 | 2021-05-06 | Freeline Therapeutics Limited | Factor viii construct |
| WO2021113800A1 (en) * | 2019-12-06 | 2021-06-10 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
| CN114981299A (zh) * | 2019-12-12 | 2022-08-30 | 武田药品工业株式会社 | 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法 |
| KR102167829B1 (ko) * | 2020-02-10 | 2020-10-20 | 주식회사 이노테라피 | 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| WO2022094461A1 (en) | 2020-11-02 | 2022-05-05 | Biomarin Pharmaceutical Inc. | Process for enriching adeno-associated virus |
| CN115554418B (zh) * | 2022-11-22 | 2023-04-14 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| CN119015447A (zh) * | 2023-09-01 | 2024-11-26 | 康霖生物科技（杭州）有限公司 | 一种缓冲系统及其相应液体制剂及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| ATE78293T1 (de) | 1983-05-27 | 1992-08-15 | Texas A & M Univ Sys | Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors. |
| ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| EP0933997A4 (en) | 1996-09-06 | 2000-08-16 | Chiron Corp | METHODS AND COMPOSITIONS FOR LIVER-SPECIFIC ADMINISTRATION OF THERAPEUTIC MOLECULES USING RECOMBINANT AAV VECTORS |
| JP2002516345A (ja) * | 1998-05-27 | 2002-06-04 | セル ジェネシス インコーポレイテッド | 第ｖｉｉｉ因子活性のアデノ随伴ウイルスベクター媒介性発現 |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| WO2003074714A1 (en) | 2002-03-05 | 2003-09-12 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
| DK1804839T3 (da) | 2004-09-22 | 2012-04-10 | St Jude Childrens Res Hospital | Forbedret ekspression af faktor ix i genterapivektorer |
| US7943374B2 (en) * | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| CA2703948A1 (en) | 2007-11-01 | 2009-05-07 | University Of Rochester | Recombinant factor viii having increased stability |
| US7943379B2 (en) | 2008-04-30 | 2011-05-17 | Nationwide Children's Hospital, Inc. | Production of rAAV in vero cells using particular adenovirus helpers |
| GB0911870D0 (en) * | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
| BR112014020325A2 (pt) | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| GB201210357D0 (en) | 2012-06-12 | 2012-07-25 | Ucl Business Plc | Factor VIII sequences |
| US20140003880A1 (en) * | 2012-06-30 | 2014-01-02 | General Electric Company | Ceramic matrix composite and metal attachment configurations |
| CA2888931C (en) * | 2012-10-26 | 2023-09-05 | Vrije Universiteit Brussel | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
| EP3044231B1 (en) * | 2013-09-12 | 2020-08-05 | BioMarin Pharmaceutical Inc. | Aav vectors comprising a gene encoding factor viii |
| AU2016219398A1 (en) | 2015-02-10 | 2017-09-28 | Genzyme Corporation | Enhanced delivery of viral particles to the striatum and cortex |
| TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| MA42934A (fr) * | 2015-09-24 | 2018-08-01 | Biomarin Pharm Inc | Vecteurs de facteur viii à virus adéno-associé, particules virales associées et formulations thérapeutiques comprenant ceux-ci |
-
2016
- 2016-09-23 MA MA042934A patent/MA42934A/fr unknown
- 2016-09-23 TW TW105130912A patent/TWI756185B/zh active
- 2016-09-23 RU RU2018114888A patent/RU2742352C2/ru active
- 2016-09-23 IL IL297353A patent/IL297353B1/en unknown
- 2016-09-23 IL IL257939A patent/IL257939B2/en unknown
- 2016-09-23 PE PE2018000419A patent/PE20181338A1/es unknown
- 2016-09-23 US US15/274,046 patent/US10512675B2/en active Active
- 2016-09-23 WO PCT/US2016/053269 patent/WO2017053677A1/en not_active Ceased
- 2016-09-23 PE PE2023002034A patent/PE20241346A1/es unknown
- 2016-09-23 TW TW111102320A patent/TWI841908B/zh active
- 2016-09-23 CA CA2999297A patent/CA2999297A1/en active Pending
- 2016-09-23 EP EP16778589.8A patent/EP3352787A1/en active Pending
- 2016-09-23 TW TW113113785A patent/TW202446416A/zh unknown
- 2016-09-23 CN CN201680056519.9A patent/CN108778323A/zh active Pending
- 2016-09-23 MX MX2018003702A patent/MX2018003702A/es unknown
- 2016-09-23 AU AU2016326602A patent/AU2016326602A1/en not_active Abandoned
- 2016-09-23 JP JP2018515603A patent/JP2018535929A/ja not_active Withdrawn
- 2016-09-23 KR KR1020187009991A patent/KR102805910B1/ko active Active
- 2016-09-23 RU RU2020126034A patent/RU2020126034A/ru unknown
- 2016-09-23 BR BR112018006074A patent/BR112018006074A2/pt not_active Application Discontinuation
-
2018
- 2018-03-09 ZA ZA2018/01657A patent/ZA201801657B/en unknown
- 2018-03-19 PH PH12018500594A patent/PH12018500594A1/en unknown
- 2018-03-21 CL CL2018000740A patent/CL2018000740A1/es unknown
-
2019
- 2019-11-06 US US16/675,841 patent/US11690898B2/en active Active
-
2021
- 2021-11-01 AU AU2021261832A patent/AU2021261832B2/en active Active
- 2021-11-08 JP JP2021181755A patent/JP2022010141A/ja active Pending
-
2023
- 2023-05-26 US US18/324,594 patent/US20240058423A1/en active Pending
-
2024
- 2024-07-26 JP JP2024120967A patent/JP2024147801A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535929A5 (enExample) | ||
| RU2018114888A (ru) | Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции | |
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| Lyden et al. | Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers | |
| Nosaka et al. | Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice | |
| JP2018138578A5 (enExample) | ||
| JP2015519382A5 (enExample) | ||
| Ehrlich et al. | Activation of the aryl hydrocarbon receptor by 10-Cl-BBQ prevents insulitis and effector T cell development independently of Foxp3+ regulatory T cells in nonobese diabetic mice | |
| JP2019515899A5 (enExample) | ||
| JP2020537637A5 (enExample) | ||
| JPWO2019222132A5 (enExample) | ||
| CN115190795A (zh) | 聚乙二醇化尿酸酶的制剂和剂量 | |
| TWI745114B (zh) | 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品 | |
| KR20220082000A (ko) | 후천성 혈우병 a의 예방 및/또는 치료에 이용되는 의약 조성물, 및 당해 의약 조성물을 포함하는 제품 | |
| CN101199845B (zh) | 一种稳定的抗IgE人源化单抗制剂 | |
| JP2017533252A (ja) | Ｃ型肝炎のための長時間作用型医薬組成物 | |
| JPWO2021168100A5 (enExample) | ||
| NZ740521B2 (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
| RU2023105585A (ru) | Стабильная экспрессия векторов на основе аденоассоциированного вируса у несовершеннолетних пациентов | |
| RU2020140634A (ru) | Стабильная экспрессия векторов на основе аденоассоциированного вируса у несовершеннолетних пациентов | |
| Mrak et al. | P160 Drug survival in SLE: real world data from the vienna lupus cohort | |
| OA17126A (en) | Pharmaceutical formulations of TNF-alpha antibodies |